The following abstracts showcase the top cutting-edge research presented at the European Society for Medical Oncology (ESMO) ...

Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

Abstracts will be made available on the ESMO I-O website on 5 December 2024 at 00:05 CET. The poster containing new data, not in the abstract, will be available on the Posters & Publications section ...

Society for Immunotherapy of Cancer (SITC) 2023 poster. 3 Paston, et al (2024). A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced ...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global ...

Unusual obsessions? The moon’s entrance to Aquarius piques taboo interests. Be aware that not everyone shares your tastes. You can indulge in kinky or unorthodox fascinations all you want ...

Details on the ESMO posters are below ... with pleiotropic causal variants that have opposing effect on risks for cancer and immune diseases, referred to as an I/O signature, observed in 3 ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious ...

TACTI-003 Cohort B: Eftilagimod Alpha (Soluble LAG-3) and Pembrolizumab in First-Line Recurrent or Metastatic Head & Neck ...

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting ...